Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
I’m plunging into psychedelia again — journalistically speaking. If you have any interesting tips on the matter, email me!
Oura deal may complicate Lilly’s GLP-1 telehealth ties
Eli Lilly already sends patients looking for a GLP-1 prescription to Counsel Health through its pharmacy platform LillyDirect. Now, smart ring maker Oura is buying Counsel, which could give Lilly a financial interest in a telehealth company it promotes. Lilly has agreed to buy $50 million in Oura stock if certain conditions are met, though the drugmaker says those conditions haven’t been met yet, STAT’s Elaine Chen writes.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
Source: www.statnews.com
